Why the study?
Venous thromboembolism carries risks of death, morbidity, and recurrence, while post-thrombotic syndrome frequently impairs quality of life following a first unprovoked event.
Does extended duration anticoagulation reduce recurrent VTE in adults with a first unprovoked VTE who have completed ≥3 months of initial anticoagulation?
Does extended duration anticoagulation reduce recurrent VTE in adults with a first unprovoked VTE who have completed ≥3 months of initial anticoagulation?
Extended anticoagulation after a first unprovoked VTE significantly reduces the risk of recurrence but does not improve post-thrombotic syndrome or quality of life, and is associated with a non-significant increase in major bleeding.
No takes yet. Share an insight, caveat, or question.
Extended anticoagulation reduces recurrent VTE after unprovoked events; confirms recurrence benefit while challenging PTS and QoL gains.
Bradbury et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: